Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: A phase III randomized controlled trial in children

Journal of Infectious Diseases

Volumn 208, Issue 4, 2013, Pages 544-553

  Langley, Joanne M ^a   Carmona Martinez, Alfonso ^b   Chatterjee, Archana ^c   Halperin, Scott A ^a   McNeil, Shelly ^a,d   Reisinger, Keith S ^d   Aggarwal, Naresh ^e   Huang, Li Min ^f   Peng, Ching Tien ^g   Garcia Sicilia, José ^h,i   Salamanca De La Cueva, Ignacio ^b   Cabañas, Fernando ^h   Treviño Garza, Consuelo ^j   Rodríguez Weber, Miguel Angel ^k   De La O, Manuel ^j   Chandrasekaran, Vijayalakshmi ^l   Dewé, Walthère ^m   Liu, Aixue ^l   Innis, Bruce L ^l   Jain, Varsha K ^l  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Instituto Hispalense de Pediatria   (Spain)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Capital Health ^*

^e Aggarwal and Associates Limited   (Canada)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY CHILDREN S HOSPITAL   (Taiwan)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ Quiron University Hospital   (Spain)

^j HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^k INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^l GLAXOSMITHKLINE   (United States)

^m GSK   (Belgium)

more..

Author keywords

Children; Immunogenicity; Influenza vaccine

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED QUADRIVALENT INFLUENZA VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADOLESCENT; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; APPETITE DISORDER; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE CONVULSION; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; TONIC CLONIC SEIZURE; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN;

CHILDREN; IMMUNOGENICITY; INFLUENZA VACCINE;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; PAIN; VACCINES, INACTIVATED; VICTORIA;

EID: 84880960419     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit263     Document Type: Article

References (21)

1. Ampofo WK, Baylor N, Cobey S, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi Viruses 2012; 6:142-52, e1-5.
2. Fiore AE, Bridges CB, Katz JM, Cox N. Inactivated influenza vaccines. In Plotkin S, Orenstein W, Offit P, eds. Vaccines. 6th ed. Elsevier Saunders, 2012:257-93.
3. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175:59-68.
4. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28(suppl 4):D45-53.
5. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149-56.
6. Influenza-associated pediatric deaths-United States, September 2010- August 2011. MMWR 2011; 60:1233-8.
7. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59:1-62.
8. Esposito S, Cantarutti L, Molteni CG, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect 2011; 62:379-87.
9. Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis 2012; 205:895-905.
10. Glezen WP, Couch RB, Taber LH, et al. Epidemiologic observations of influenza B virus infections in Houston, Texas, 1976-1977. Am J Epidemiol 1980; 111:13-22.
11. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8.
12. Hehme NW, Künzel W, Petschke F, et al. Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™. Clin Drug Invest 2002; 22:751-69.
13. US Food and Drug Administration. Guidance for Industry. Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. 2007 http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm 091990.pdf. Accessed 27 March 2013.
14. Public Health Agency of Canada National Advisory Committee on Immunization. Statement on Influenza for 2011-2012. Can Comm Dis Report 2011; 37:1-55. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-5/.
15. Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics 2011; 128:e276-89.
16. Langley JM, Vanderkooi OG, Garfield H, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: a randomized, controlled trial. J Pediatric Infect Dis Soc 2012; 1:55-63.
17. Skowronski DM, Hottes TS, De Serres G, et al. Influenza Beta/Victoria antigen induces strong recall of Beta/Yamagata but lower Beta/Victoria response in children primed with two doses of Beta/Yamagata. Pediatr Infect Dis J 2011; 30:833-9.
18. Gilca V, De Serres G, Hamelin ME, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 2011; 30:35-41.
19. Food and Drug Administration. FDA approves first quadrivalent vaccine to prevent seasonal influenza. 2012. http://www.fda.gov/News Events/Newsroom/ PressAnnouncements/ucm294057.htm. Accessed 17 March 2013.
20. US Food and Drug Administration. Fluarix quadrivalent. In: US Food and Drug Administration, ed. 2013. US Department of Health and Human Services, Washington, DC.
21. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013 southern hemisphere influenza season. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/vaccines/virus/ recommendations/201209-recommendation. pdf. Accessed 3 October 2012.